Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. “We rema...
BRT Apartments Corp. Files Second Quarter 2025 Financial Statements GREAT NECK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, announced today that it has filed its quarterly report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that ow...
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast . A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, , and a replay will be archived on the ...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Easter...
BRT Apartments Corp. Announces the Acquisition of Apartment Complex in Auburn, Alabama GREAT NECK, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, today announced the acquisition of 1322 North, a 214-unit Class A apartment complex in Auburn, Alabama. The acquisition of 1322 North complements BRT’s ownership of The Village at Lakeside, an Auburn, Alabama property it has owned since 2019. The properties are located one mile from each other and near the region’s two largest employers, Auburn University and East Alabama Medical Center....
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based ...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pur...
BRT Apartments Corp. Announces Quarterly Dividend GREAT NECK, N.Y., June 04, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable on July 9, 2025, to stockholders of record at the close of business on June 25, 2025. BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that own multi-family properties. As of March 31, 2025, BRT owns or has interests in 29 multi-family properties with 7,947 units in 11 sta...
A director at BRT Apartments Corp bought 19,360 shares at 15.559USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.